Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

BOTULINUM TOXIN - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Product Segments: Cosmetic Applications, and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, & Spasticity). The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets.The report profiles 22 companies including many key and niche players such as Allergan, Inc., Ipsen Group, Lanzhou Institute of Biological Products, Metabiologics, Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, Medy-Tox Incorporated, Medicis Pharmaceutical Corporation, and Solstice Neurosciences, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1833
Price : $4500
Companies : 22
Pages : 213
Date : October 2011
Market Data Tables : 74
Status: * New Report

Complimentary Report Insights:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  BOTULINUM TOXIN (Complete Report) Pages : 213   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.....I-14 $295  
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Cosmetic Applications.....I-4
Therapeutic Applications.....I-4
  
  2. INDUSTRY OVERVIEW.....II-53 $295  
   A Prelude.....II-5
Current and Future Scenario.....II-5
By Geographic Region.....II-5
By Application.....II-5
1$100
   Botulinum Toxin: “The Science, The Hopes & the Risks”.....II-6
Future Opportunities Span Beyond The Developed Markets.....II-6
2$200
  3. TRENDS & ISSUES.....II-814 $1450  
   Acceptance for Cosmetic BTX Treatment Grows.....II-8
Aging Population: A Weighty Demographic Driver.....II-8
Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or
  Jubilation?.....II-8
1$100
   Urgent Need for Physician Education about Off Label Usage.....II-9
High Voltage Ad Campaigns Boost Patient Awareness.....II-9
Societal Pressure to Look Young Drives up Demand for Facial Aesthetics.....II-9
1$100
   Cosmetic Botulinum Toxin to Feel the Pinch of the Recession.....II-10
Financing of Non-Reimbursed Healthcare: The Need of the Hour.....II-10
1$100
   Combination Therapies: A Double Whammy Success.....II-11
Short Lived Aesthetic Effects: A Strong Business Case for Revision Treatments.....II-11
1$100
   Consolidation Blows in the Aesthetic Healthcare Industry.....II-12
Undesirable Side Effects: A Challenge to Reckon With.....II-12
Immunogenicity Undermines Patient Compliance.....II-12
1$100
   Antigenicity: One of the Most Problematic Issues in Drug Development.....II-13
Stringent Regulations Delay Market Approval & Put Reimbursements in Limbo.....II-13
Non-Injectable Alternatives to Turn On the Heat.....II-13
1$100
   Fears of Terrorism & Biological Warfare Thwart International Trade.....II-14
Competition.....II-14
Allergan Wields the Scepter.....II-14
1$100
   Table 1: European Market for Non-Surgical Cosmetic Procedures (2010): Percentage Share Breakdown of Revenues by Leading Players – Allergan, Q-Med, Mentor Corporation, Mattioli Engineering, and Others (includes corresponding Graph/Chart).....II-15

Table 2: European Market for Non-Surgical Cosmetic Procedures (2010): Percentage Breakdown of Revenues by Type of Procedure –Cosmetic Botulinum Toxin Injections, Facial Fillers, Microdermabrasion, Chemical Peeling, and Aesthetic Lasers (includes corresponding Graph/Chart).....II-15
1$350
   Reloxin Emerges to Threaten Allergan’s Dominance.....II-16
Reloxin Vs Botox: A Comparison.....II-16
1$100
   Outlook for Allergan’s Botox.....II-171$100
   Market Share Statistics.....II-18
Global.....II-18
Table 3: World Market for Therapeutic Neurotoxins (2010): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan), Dysport (Ispen), Myobloc (Solstice), and Others (includes corresponding Graph/Chart).....II-18

Table 4: World Market for Cosmetic Neurotoxins (2010): Percentage Breakdown of Revenues by Company/Brand –Botox/Vistabel (Allergan) and Dysport/Reloxin (Ipsen/Medicis) (includes corresponding Graph/Chart).....II-18
Europe.....II-18
Table 5: European Market for Cosmetic Neurotoxins (2010): Percentage Breakdown of Revenues by Company/ Brand –Botox/Vistabel (Allergan) and Dysport (Ipsen) (includes corresponding Graph/Chart).....II-18
1$350
   Table 6: European Market for Therapeutic Neurotoxins (2010): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan), Dysport (Ispen), and Others (includes corresponding Graph/Chart).....II-19
United States.....II-19
Table 7: US Market for Therapeutic Neurotoxins (2010): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan) and Myobloc (Solstice) (includes corresponding Graph/Chart).....II-19
Market Share Statistics: Through the Looking Glass: Year 2012.....II-19
Global.....II-19
Table 8: World Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/ Brand –Botox (Allergan), Dysport (Ispen), Myobloc (Solstice), Puretox (Mentor), Xeomin (Merz), and Others (includes corresponding Graph/Chart).....II-19
1$350
   Table 9: World Market for Cosmetic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan), Dysport/Reloxin (Ipsen/Medicis), Xeomin (Merz), and Puretox (Mentor) (includes corresponding Graph/Chart).....II-20
United States.....II-20
Table 10: US Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan), Myobloc (Solstice), Dysport (Ispen), Puretox (Mentor) and Xeomin (Merz) (includes corresponding Graph/Chart).....II-20

Table 11: US Market for Cosmetic Neurotoxins (2008 & 2012P): Percentage Breakdown of Revenues by Company/ Brand –Botox (Allergan), Reloxin (Medicis), and Puretox (Mentor) (includes corresponding Graph/Chart).....II-20
1$350
   Europe.....II-21
Table 12: European Market for Therapeutic Neurotoxins (2012P): Percentage Breakdown of Revenues by Company/Brand –Botox (Allergan), Dysport (Ispen), Xeomin (Merz) and Neurobloc (Solstice) (includes corresponding Graph/Chart).....II-21
1$350
  4. PRODUCT OVERVIEW.....II-2213 $950  
   Botulinum Toxin: A Poison That Cures.....II-22
Structure & Mechanism of Action.....II-22
1$100
   Disadvantages.....II-23
Classification of Botulinum Toxin.....II-23
Botulinum Toxin Type A.....II-23
1$100
   Historical Timeline of Botulinum Toxin: 1885-2002.....II-24
Botox®.....II-24
1$100
   Key Characteristics of Botox® and Botox® Cosmetic.....II-25
Approvals and Indications of Botox in Select Regions.....II-25
1$100
   Common Adverse Reactions with Botox.....II-26
Dysport®/ Reloxin®.....II-26
Key Characteristics of Dysport®.....II-26
1$100
   PurTox®.....II-27
Key Characteristics of PurTox®.....II-27
Xeomin®/ NT-201.....II-27
Key Characteristics of Xeomin®/ NT-201.....II-27
1$100
   Botulinum Toxin Type B.....II-28
Myobloc®/NeuroBloc®.....II-28
Key Characteristics of Myobloc®.....II-28
1$100
   Applications of Botulinum Toxin.....II-29
Cosmetic Applications.....II-29
Glabellar Lines.....II-29
Facial Wrinkles.....II-29
1$100
   Key Cosmetic Indications for Botulinum Toxin.....II-30
Therapeutic Applications.....II-30
Movement Disorders/Pain.....II-30
Cervical Dystonia.....II-30
1$100
   Hemifacial Spasm.....II-31
Blepharospasm.....II-31
Strabismus.....II-31
Chronic Pain.....II-31
1$100
   Botox in Migraine Treatment.....II-32
Hyperhidrosis.....II-32
1$100
   Bladder Dysfunctions.....II-33
Spasticity.....II-33
Other Applications.....II-33
2$200
  5. PRODUCT APPROVALS & INTRODUCTIONS.....II-356 $495  
   SMC Approves the Use of Botox® for the Treatment of Focal Spasticity.....II-35
Merz Launches Xeomin in the US.....II-35
Ipsen Launches Dysport in US.....II-35
1$100
   Ipsen and Medicis Receives FDA Approval for DysportTM.....II-36
Xeomin Receives Approval From European Health Authorities.....II-36
Ranbaxy and MedyTox Collaborates to Launch Neuronox.....II-36
GlaxoSmithKline Receives Approval for Botox Vista.....II-36
1$100
   Galderma and Ipsen Obtain Marketing Authorization for Azzalure.....II-37
Azzalure® Gains Approval from 15 European Countries.....II-37
Inclusion of New Side Effect in Botox and Botox Cosmetic Labels.....II-37
1$100
   Azzalure® Gains Approval for Aesthetic Application in the UK.....II-38
Ipsen and Medicis File BLA for Reloxin®.....II-38
Allergan and Clinique Launch New Skin Care Products.....II-38
FDA Accepts Ipsen's Filing for Reloxin.....II-38
1$100
   GlaxoSmithKline Gains Approval for BOTOX® in Japan.....II-39
Mentor Completes Phase IIIb Trial for Its Botulinum Toxin Type A Product.....II-39
Allergan Commences Botox Study for Urological Cases in India.....II-39
FDA Accepts BLA Filing for Dysport® in Cervical Dystonia Cases.....II-39
1$100
   Allergan Successfully Completes Analysis of Two Phase III Trials for BOTOX®.....II-40
Allergan to Launch New Products in India.....II-40
1$100
  6. RECENT INDUSTRY ACTIVITY.....II-414 $395  
   US WorldMeds Takes Over Solstice Neurosciences.....II-41
Johnson & Johnson Acquires Mentor Corporation.....II-41
1$100
   Ranbaxy Signs an in-Licensing Agreement with Medy-Tox.....II-42
Ranbaxy Signs Marketing Agreement with MedyTox.....II-42
Revance and Medicis Sign Licensing Agreement.....II-42
GlaxoSmithKline and Wakamoto Pharmaceutical Collaborate to Market Botox.....II-42
1$100
   BioForm Medical Acquires Advanced Cosmetic Intervention.....II-43
Galderma to Acquire CollaGenex.....II-43
Allergan and Clinique Form Strategic Collaboration.....II-43
Allergan to Set Up a New Subsidiary in India.....II-43
1$100
   Allergan Join Hands with India–Based Kaya.....II-44
Q-Med and Medy-Tox Cancel the Collaboration Agreement.....II-44
Galderma to Increase Awareness in Brazil.....II-44
Galderma Receives License to Market Dysport.....II-44
1$100
  7. FOCUS ON SELECT KEY PLAYERS.....II-453 $295  
   Allergan, Inc. (US).....II-45
Ipsen Group (France).....II-45
Lanzhou Institute of Biological Products (China).....II-45
1$100
   Metabiologics, Inc. (US).....II-46
Merz Pharmaceuticals GmbH (Germany).....II-46
Mentor Corporation (US).....II-46
Medy-Tox Incorporated (South Korea).....II-46
1$100
   Medicis Pharmaceutical Corporation (US).....II-47
Solstice Neurosciences, Inc. (US).....II-47
1$100
  8. GLOBAL MARKET PERSPECTIVE.....II-48   
   Table 13: World Recent Past, Current & Future Analysis for Botulinum Toxin by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-481$350
   Table 14: World Historic Review for Botulinum Toxin by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million For the Years 2003 through 2008 (includes corresponding Graph/Chart).....II-491$350
   Table 15: World 15-Year Perspective for Botulinum Toxin by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-501$350
   Table 16: World Recent Past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-511$350
   Table 17: World Historic Review for Botulinum Toxin in Cosmetic Applications by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....II-521$350
   Table 18: World 15-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-531$350
   Table 19: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-541$350
   Table 20: World Historic Review for Botulinum Toxin in Therapeutic Applications by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....II-551$350
   Table 21: World 15-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-561$350
   Table 22: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Application by Disease Indication – Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity– Markets Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-571$350
   Table 23: World Historic Review for Botulinum Toxin in Therapeutic Application by Disease Indication – Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity – Markets Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-581$350
   Table 24: World 15-Year Perspective for Botulinum Toxin in Therapeutic Application by Disease Indication – Percentage Breakdown of Dollar Sales for Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity – Markets for the Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-591$350
  9. THE UNITED STATES.....II-6016 $2450  
   A. Market Analysis.....II-60
Current and Future Scenario.....II-60
By Application.....II-60
Cosmetic Procedures: An Overview.....II-60
1$100
   Botox Leads the US Botulinum Toxin Market.....II-61
Botox Approvals and Indications in the US.....II-61
1$100
   Major Market Trends.....II-62
Botulinum Toxin to Drive Growth in the Facial Aesthetics Market.....II-62
Booming Non-Surgical Treatments.....II-62
Aging Baby Boomers Drive Aesthetic Business.....II-62
Expanding Physician Base Extends Impetus to Growth.....II-62
1$100
   Demand for Professional Help On the Rise.....II-63
Direct-to-Consumer Advertising Drive Cosmetic Botulinum Toxin.....II-63
Botulism Poisoning: A Major Concern.....II-63
Botox Injection – Popular Non-Invasive Cosmetic Procedure.....II-63
1$100
   Product Approvals and Introductions.....II-642$200
   Strategic Corporate Developments.....II-662$200
   Key Players.....II-682$200
   B. Market Analytics.....II-70
Table 25: US Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-70
1$350
   Table 26: US Historic Review for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....II-711$350
   Table 27: US 15-Year Perspective for Botulinum Toxin by Application – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications Markets for the Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-721$350
   Table 28: US Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Disease Indication – Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity- Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-731$350
   Table 29: US Historic Review for Botulinum Toxin in Therapeutic Application by Disease Indication – Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-741$350
   Table 30: US 15-Year Perspective for Botulinum Toxin in Therapeutic Application by Disease Indication – Percentage Breakdown of Dollar Sales for Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity for the Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-751$350
  10. EUROPE.....II-769 $1995  
   A. Market Analysis.....II-76
Current and Future Scenario.....II-76
By Application.....II-76
European BTX Cosmetics Treatments Market - A Primer.....II-76
Botox Approvals and Indications in Select European Countries.....II-76
1$100
   Botox to Support Radiation Treatments.....II-77
Product Approvals and Introductions.....II-77
1$100
   Key Players.....II-781$100
   B. Market Analytics.....II-79
Table 31: European Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-79
1$350
   Table 32: European Historic Review for Botulinum Toxin by Application –Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....II-801$350
   Table 33: European 15-Year Perspective for Botulinum Toxin by Application – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications Markets for the Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-811$350
   Table 34: European Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Disease Indication – Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity- Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-821$350
   Table 35: European Historic Review for Botulinum Toxin in Therapeutic Application by Disease Indication – Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity - Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-831$350
   Table 36: European 15-Year Perspective for Botulinum Toxin in Therapeutic Application by Disease Indication – Percentage Breakdown of Dollar Sales for Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity- Markets for the Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-841$350
  11. REST OF WORLD.....II-8513 $2450  
   A. Market Analysis.....II-85
Current and Future Scenario.....II-85
By Applications.....II-85
A Peek into Select Market.....II-85
India – An Emerging Market for Botox.....II-85
Competitive Landscape in South Korea.....II-85
1$100
   Table 37: Korean Botulinum Toxin Market (2010): Percentage Breakdown of Sales by Leading Players -Medy-Tox, Allergan, Ipsen, and Lanzhou Institute (includes corresponding Graph/Chart).....II-86
Australia – A Well Supported Market.....II-86
Botox Approvals and Indications in Select Asian Countries.....II-86
1$350
   Latin America- Cosmetic Surgery Market.....II-87
Botox Approvals and Indications in Select Latin American Regions.....II-87
Botox Approvals and Indications in Other Select Global Regions.....II-87
1$100
   Product Approvals and Introductions.....II-88
Strategic Corporate Developments.....II-88
3$300
   Key Players.....II-911$100
   B. Market Analytics.....II-92
Table 38: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2017) (includes corresponding Graph/Chart).....II-92
1$350
   Table 39: Rest of World Historic Review for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2003 through 2008 (includes corresponding Graph/Chart).....II-931$350
   Table 40: Rest of World 15-Year Perspective for Botulinum Toxin by Application – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications Markets for the Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-941$350
   Table 41: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Disease Indication – Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity- Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2017 (includes corresponding Graph/Chart).....II-951$350
   Table 42: Rest of World Historic Review for Botulinum Toxin in Therapeutic Application by Disease Indication – Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-961$350
   Table 43: Rest of World 15-Year Perspective for Botulinum Toxin in Therapeutic Application by Disease Indication – Percentage Breakdown of Dollar Sales for Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity for the Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-971$350
COMPETITION 109$995
  
Total Companies Profiled: 22 (including Divisions/Subsidiaries - 26)

Region/Country                 Players


The United States                 10   
Japan                              3
Europe                             6
     France                        1
     Germany                       2
     The United Kingdom            2
     Rest of Europe                1
Asia-Pacific (Excluding Japan)     7
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign